<--- Back to Details
First PageDocument Content
Microbiology / Viral hepatitis / Hepatitis B / AIDS / Hepatitis C / Antiretroviral drug / Viral load / HIV / Hepatitis / Medicine / Health / HIV/AIDS
Date: 2013-11-12 03:04:09
Microbiology
Viral hepatitis
Hepatitis B
AIDS
Hepatitis C
Antiretroviral drug
Viral load
HIV
Hepatitis
Medicine
Health
HIV/AIDS

Add to Reading List

Source URL: cmp.thebumpwa.org.au

Download Document from Source Website

File Size: 530,04 KB

Share Document on Facebook

Similar Documents

Acute Hepatitis C in the PROUD pilot study Juan Tiraboschi, Liz Brodnicki, Brady Michael, John Saunders, Schembri Gabriel, Mark Roche, Julie Fox on behalf of the PROUD study

DocID: 1vngt - View Document

PRESS RELEASE AbbVie Receives Health Canada Approval of HOLKIRATM PAK for the Treatment of Chronic Genotype 1 Hepatitis C  New all-oral, short-course (12 weeks), interferon-free treatment available in Canada for geno

DocID: 1vlwz - View Document

PRESS RELEASE AbbVie’s MAVIRET™ Approved by Health Canada for the Treatment of Chronic Hepatitis C in All Major Genotypes   

DocID: 1vjI2 - View Document

Contact PD/PI: Braithwaite, Ronald Scott A. SPECIFIC AIMS Many persons with HIV have Hepatitis C (HCV) co-infection and consume alcohol.1,2 Now that highly effective and easily tolerated therapies for HCV are available,

DocID: 1vbzY - View Document

PRESS RELEASE AbbVie’s TECHNIVIE™ Receives Health Canada Approval for Genotype 4 Chronic Hepatitis C Infection  TECHNIVIE provides an opportunity to treat adults who have genotype 4 (GT4) chronic hepatitis C

DocID: 1vais - View Document